Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...

USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

根据最新的SEC文件显示，Neurocrine Biosciences Inc. (NASDAQ: NBIX )的首席医疗官Eiry ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.

Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time ...

Neurocrine Biosciences Inc (NBIX) reports robust sales growth and strategic investments amid competitive pressures and payer challenges.

市值154亿美元的生物制药公司Neurocrine Biosciences Inc. (NASDAQ: NBIX )年初至今取得了11.7%的亮眼回报。根据提交给证券交易委员会的文件显示，公司首席财务官Matt ...

Neurocrine Biosciences (NBIX) announced it has amended its agreement with Takeda (TAK) to develop and commercialize osavampator. Under the ...

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...